Oral Statins and Protection From Hearing Loss
ConditionSudden Sensorineural Hearing Loss
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorNorthwestern University
About this trial
A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone) improve the treatment outcome for patients with ISSNHL? This study will compare the two treatments and quantitatively evaluate hearing and speech discrimination and have the patients subjectively evaluate tinnitus.
Eligibility criteria
Qualifiers
Patient older than 18 years and younger than 81 years and
Diagnosed with one sided idiopathic sudden sensorineural hearing loss by physical examination, history, audiology, speech interpretation tests and tinnitus evaluation and
Seen in the clinic within the first 14 days after the onset of symptoms. and
Mean hearing threshold equal to or worse than >30 dB averaged across three consecutive frequencies.
Disqualifiers
Children
Prisoners
Pregnant women
Patients who have experienced similar prior events of SSNHL
Trial design
Treatments tested in this trial
- Statin
- methylprednisolone
- dexamethasone
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov